- Home
- UTG vs IOVA Comparison
UTG vs IOVA Comparison
Compare UTG & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTG
- IOVA
- Stock Information
- Founded
- UTG 2003
- IOVA 2007
- Country
- UTG United States
- IOVA United States
- Employees
- UTG N/A
- IOVA N/A
- Industry
- UTG Investment Managers
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UTG Finance
- IOVA Health Care
- Exchange
- UTG Nasdaq
- IOVA Nasdaq
- Market Cap
- UTG 2.8B
- IOVA 2.6B
- IPO Year
- UTG N/A
- IOVA N/A
- Fundamental
- Price
- UTG $33.59
- IOVA $5.91
- Analyst Decision
- UTG
- IOVA Strong Buy
- Analyst Count
- UTG 0
- IOVA 9
- Target Price
- UTG N/A
- IOVA $23.33
- AVG Volume (30 Days)
- UTG 319.3K
- IOVA 9.1M
- Earning Date
- UTG 01-01-0001
- IOVA 02-26-2025
- Dividend Yield
- UTG 9.31%
- IOVA N/A
- EPS Growth
- UTG N/A
- IOVA N/A
- EPS
- UTG N/A
- IOVA N/A
- Revenue
- UTG N/A
- IOVA $90,858,000.00
- Revenue This Year
- UTG N/A
- IOVA $13,758.71
- Revenue Next Year
- UTG N/A
- IOVA $171.20
- P/E Ratio
- UTG N/A
- IOVA N/A
- Revenue Growth
- UTG N/A
- IOVA 12751.20
- 52 Week Low
- UTG $23.24
- IOVA $5.62
- 52 Week High
- UTG $29.50
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- UTG 62.25
- IOVA 28.87
- Support Level
- UTG $31.35
- IOVA $5.62
- Resistance Level
- UTG $32.80
- IOVA $6.44
- Average True Range (ATR)
- UTG 0.50
- IOVA 0.45
- MACD
- UTG 0.21
- IOVA -0.10
- Stochastic Oscillator
- UTG 93.13
- IOVA 11.46
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.